We've announced the results from our 2026 Annual General Meeting of Shareholders held virtually on June 24, 2026.
A webcast of the AGM will be accessible under “Events & Presentations” in the Investors section of the Cardiol website.
$CRDL
Cardiol Therapeutics Inc.
755 posts
Cardiol Therapeutics Inc.
@CardiolRx
- Reminder: Cardiol Therapeutics’ virtual Annual General Meeting of Shareholders begins in 30 minutes. The AGM will be webcast today at 4:30 p.m. EDT. Join here: meetings.400.lumiconnect.com/r/participant/… $CRDL
- Today we announced that our 2026 Annual General Meeting of Shareholders will be held virtually on June 24, 2026 at 4:30 p.m. EDT. $CRDL cardiolrx.com/cardiol-therap…Access the live webcast: meetings.lumiconnect.com/400-405-294-535 Additional details, including how to participate and vote, are available at: cardiolrx.com/investors/even…
- We're building toward multiple high-impact milestones — all tied to one mission: treating inflammation in heart disease. Pivotal Phase III MAVERIC topline data. CRD-38 IND submission. Rare disease expansion. Strategic partnerships. The key catalysts are lined up. $CRDL
- Inflammation doesn't stop when symptoms do — and the structural consequences show up in the data. In our ARCHER trial, CardiolRx™ reduced left ventricular (LV) mass by 9.2 grams in patients with acute myocarditis — comparable to reductions seen with widely prescribed therapies
- A person with recurrent pericarditis knows the feeling. The pain subsides. Life starts to normalize. And then, weeks or months later, it comes back. That cycle of recurrence is one of the most difficult aspects of the disease. Treatments that provide short-term relief matter.
- From approximately six episodes per year to less than one. CEO David Elsley discusses the Phase II MAvERIC findings in recurrent pericarditis, and how those data helped form the basis for the now-enrolling pivotal Phase III MAVERIC trial. $CRDL
00:00 - Cardiol's President/CEO David Elsley sat down with Stocks to Watch to discuss our approach to targeting inflammation in heart disease — and what's ahead for $CRDL. 🎥 Watch the full interview: youtube.com/watch?v=NXkzgf… #HeartDisease #Biotech #CRDL #Pericarditis #Inflammation
- REPLAY: President/CEO David Elsley & CMO/Head of R&D Andrew Hamer joined @HCWCO yesterday in a Fireside Chat hosted by Brandon Folkes to discuss the pivotal Phase III MAVERIC trial, key value-driving milestones, and development of CRD-38. 🔗 Watch here: journey.ct.events/view/8d043006-…
- REMINDER: Cardiol Therapeutics will be presenting a Fireside Chat today at 1:30 p.m. ET at the H.C. Wainwright 4th Annual BioConnect Investor Conference at the Nasdaq in New York City. $CRDL 📺Watch our Fireside Chat live via webcast — register here: journey.ct.events/view/8d043006-…
- We’re proud to support @PericarditisA 1st Annual Platypus Run on May 16, 2026! The event helps raise awareness of pericarditis and brings together patients, families, and supporters through a 5K run, 1-mile walk, and virtual participation option. We’re pleased to stand with TheThe Platypus Run is almost here! If you’re joining us in Albuquerque, we’ll see you Saturday, May 16 at 8:30am MDT. Participating virtually? You can complete your run or walk anytime during the week of May 16–23, wherever it works best for you! pericarditisalliance.org/events/
- Very informative paper from the great team of our MAVERIC trial collaborators at the @ClevelandClinic!Important article how to use multimodality imaging for pericarditis. Congratulations to our pericardial team
